Pretreatment eosinophil counts as a predictive biomarker in non‐small cell lung cancer patients treated with immune checkpoint inhibitors

Abstract

AbstractBackgroundThe peripheral blood eosinophil count prior to treatment has potential as a predictive biomarker for a beneficial clinical response to cancer immunotherapies. Therefore, the present study investigated the impact of the eosinophil count on overall survival (OS) in non‐small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICI).MethodsWe retrospectively reviewed all patients diagnosed with NSCLC and treated with ICI monotherapy between March 2016 and August 2021 at National Hospital Organization Kochi Hospital and Tokushima University.ResultsA total of 166 patients were included. Fifty‐five patients had an eosinophil count of less than 100 cells/μL (Eo < 100). Nighty‐eight patients had an eosinophil count of 100 cells/μL or more, but less than 500 cells/μL (100 ≤ Eo < 500). Thirteen patients had an eosinophil count of 500 cells/μL or more (Eo ≥500). The median OS of all lung cancer patients was 476 days. The median OS of lung cancer patients with Eo <100, 100 ≤ Eo <500, and Eo ≥500 was 339, 667, and 143 days, respectively. A Kaplan–Meier univariate analysis showed a significant difference in OS between these three groups (p < 0.001). A Cox proportional regression analysis identified 100 ≤ Eo <500 (p = 0.04), ECOG PS score ≥ 2 (p = 0.02), tumor size ≥5 cm (p = 0.02), and PD‐L1 ≥ 1% (p = 0.01) as independent predictors of OS.ConclusionOS was significantly longer in ICI‐treated NSCLC patients with a pretreatment eosinophil count of 100 ≤ Eo <500 than in the other patients and, thus, has potential as a new predictive biomarker.